Science | Nature | Cell | View More
Natural Products
Sorafenib
Sorafenib
ChemFaces products have been cited in many studies from excellent and top scientific journals
Product Name Sorafenib
Price: $30 / 20mg
CAS No.: 284461-73-0
Catalog No.: CFN90012
Molecular Formula: C21H16ClF3N4O3
Molecular Weight: 464.83 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Download: COA    MSDS    SDF
Similar structural: Comparison (Web)  (SDF)
Guestbook:
Contact Us
Order & Inquiry & Tech Support

Tel: (0086)-27-84237683
Tech: service@chemfaces.com
Order: manager@chemfaces.com
Address: 176, CheCheng Eest Rd., WETDZ, Wuhan, Hubei 430056, PRC
How to Order
Orders via your E-mail:

1. Product number / Name / CAS No.
2. Delivery address
3. Ordering/billing address
4. Contact information
Order: manager@chemfaces.com
Delivery time
Delivery & Payment method

1. Usually delivery time: Next day delivery by 9:00 a.m. Order now

2. We accept: Wire transfer & Credit card & Paypal
Citing Use of our Products
* Packaging according to customer requirements(5mg, 10mg, 20mg and more). We shipped via FedEx, DHL, UPS, EMS and others courier.
According to end customer requirements, ChemFaces provide solvent format. This solvent format of product intended use: Signaling Inhibitors, Biological activities or Pharmacological activities.
Size /Price /Stock 10 mM * 1 mL in DMSO / $12.7 / In-stock
Other Packaging *Packaging according to customer requirements(100uL/well, 200uL/well and more), and Container use Storage Tube With Screw Cap
Our products had been exported to the following research institutions and universities, And still growing.
  • Sant Gadge Baba Amravati Univer... (India)
  • Universidade Federal de Santa C... (Brazil)
  • Leibniz-Institut für Pflanzenb... (Germany)
  • Florida International University (USA)
  • Julius Kühn-Institut (Germany)
  • Universidade Federal de Pernamb... (Brazil)
  • University of Brasilia (Brazil)
  • Chang Gung University (Taiwan)
  • China Medical University (Taiwan)
  • Charles University in Prague (Czech Republic)
  • Institute of Tropical Disease U... (Indonesia)
  • More...
Package
Featured Products
Rhapontigenin

Catalog No: CFN92607
CAS No: 500-65-2
Price: $118/20mg
L-Valine

Catalog No: CFN94831
CAS No: 72-18-4
Price: $30/20mg
Procyanidin A1

Catalog No: CFN96495
CAS No: 103883-03-0
Price: $288/20mg
Calycosin

Catalog No: CFN99140
CAS No: 20575-57-9
Price: $80/20mg
Diallyl disulfide

Catalog No: CFN93237
CAS No: 2179-57-9
Price: $50/20mg
Platycoside E

Catalog No: CFN90786
CAS No: 237068-41-6
Price: $ / mg
Mangiferin

Catalog No: CFN98719
CAS No: 4773-96-0
Price: $40/20mg
Ginkgolide B

Catalog No: CFN99640
CAS No: 15291-77-7
Price: $40/20mg
Chebulinic acid

Catalog No: CFN92296
CAS No: 18942-26-2
Price: $138/20mg
Oxypeucedanin

Catalog No: CFN90350
CAS No: 737-52-0
Price: $80/20mg
Related Screening Libraries
Size /Price /Stock 10 mM * 100 uL in DMSO / Inquiry / In-stock
10 mM * 1 mL in DMSO / Inquiry / In-stock
Related Libraries
Biological Activity
Description: Sorafenib is a potent multikinase inhibitor with IC50s of 6 nM, 20 nM, and 22 nM for Raf-1, B-Raf, and VEGFR-3, respectively.Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC. The combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials.
Targets: AMPK | Wnt/β-catenin | mTOR | ERK | VEGFR-3 | B-Raf | Raf-1
In vitro:
Biochem Biophys Res Commun. 2015 Apr 3;459(2):234-9.
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.[Pubmed: 25712526]
Chemotherapy-induced autophagy activation often contributes to cancer resistance. MiRNA-30a (miR-30a) is a potent inhibitor of autophagy by downregulating Beclin-1. In this study, we characterized the role of miR-30a in Sorafenib-induced activity in renal cell carcinoma (RCC) cells.
METHODS AND RESULTS:
We found that expression of miR-30a was significantly downregulated in several human RCC tissues and in RCC cell lines. Accordingly, its targeted gene Beclin-1 was upregulated. Sorafenib activated autophagy in RCC cells (786-0 and A489 lines), evidenced by p62 degradation, Beclin-1/autophagy protein 5 (ATG-5) upregulation and light chain (LC)3B-I/-II conversion. Exogenously expressing miR-30a in 786-0 or A489 cells inhibited Beclin-1 expression and enhanced Sorafenib-induced cytotoxicity. In contrast, knockdown of miR-30a by introducing antagomiR-30a increased Beclin-1 expression, and inhibited Sorafenib-induced cytotoxicity against RCC cells. Autophagy inhibitors, including chloroquine, 3-methyaldenine or Bafliomycin A1, enhanced Sorafenib activity, causing substantial cell apoptosis. Meanwhile, knockdown of Beclin-1 or ATG-5 by targeted siRNAs also increased Sorafenib-induced cytotoxicity in above RCC cells.
CONCLUSIONS:
These findings indicate that dysregulation of miR-30a in RCC may interfere with the effectiveness of Sorafenib-mediated apoptosis by an autophagy-dependent pathway, thus representing a novel potential therapeutic target for RCC.
In vivo:
Jpn J Clin Oncol. 2015 Apr;45(4):336-42.
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.[Pubmed: 25646358]
Sorafenib is a recommended treatment for advanced hepatocellular carcinoma. The study is to evaluate the efficacy of Sorafenib plus cyproheptadine compared with Sorafenib alone in patients with advanced hepatocellular carcinoma.
METHODS AND RESULTS:
A retrospective cohort study reviewed all consecutive advanced hepatocellular carcinoma cases with Child-Pugh Class A disease starting Sorafenib treatment at our hospital from August 2012 to March 2013. They were followed up until 31 December 2013. A total of 52 patients were enrolled: 32 patients in the combination (Sorafenib-cyproheptadine) group and 20 patients in the control (Sorafenib alone) group. The response to treatment, overall survival and progression-free survival were compared. The median overall survival was 11.0 months (95% confidence interval: 6.8-15.1 months) in the combination group compared with 4.8 months (95% confidence interval: 3.1-6.6 months) in the control group (crude hazard ratio = 0.45, 95% confidence interval: 0.22-0.82). The median progression-free survival time was 7.5 months (95% confidence interval: 5.1-10.0 months) in the combination group compared with 1.7 months (95% confidence interval: 1.4-2.1 months) in the control group (crude hazard ratio = 0.43, 95% confidence interval: 0.22-0.86). Kaplan-Meier survival analysis revealed that both overall survival and progression-free survival in the combination group were significantly longer than that in the control group. The multivariate model found patients in the combination group were 76% less likely to die (adjusted hazard ratio = 0.24, 95% confidence interval: 0.10-0.58) and 82% less likely to have progression (adjusted hazard ratio = 0.18, 95% confidence interval: 0.08-0.44) during the 17 months of follow-up.
CONCLUSIONS:
Cyproheptadine may significantly improve survival outcomes of Sorafenib-treated advanced hepatocellular carcinoma patients.
Anticancer Res. 2015 Mar;35(3):1803-8.
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.[Pubmed: 25750346]
Sorafenib is the medical reference for treatment of hepatocellular carcinoma (HCC). Multiple forms of cytotoxicity are induced by Sorafenib in HCC cells in vitro but it is unclear what extent of apoptosis and necrosis is induced in HCC patients receiving Sorafenib.
METHODS AND RESULTS:
The M30 and M65 biomarkers, which reflect the release of cytokeratin-18 and its apoptotic cleavage fragments, were measured in patients with HCC (n=36) and matched patients with cirrhosis (n=47). A serum sample was collected from 20 patients with HCC four weeks after the onset of treatment with Sorafenib. Basal serum levels of M30 and M65 were increased in patients with HCC compared to those with uncomplicated cirrhosis. No statistically significant increase in the level of M30 or M65 was found in the sera of patients with HCC after Sorafenib.
CONCLUSIONS:
The findings indicate that Sorafenib is not a potent inducer of HCC cell death in most patients.
Sorafenib Description
Source:
Solvent: DMSO, Pyridine, Methanol, Ethanol, etc.
Storage: Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

After receiving: The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
ChemFaces New Products and Compounds
Naringenin 7-O-gentiobioside

Catalog No: CFN95435
CAS No: 104154-33-8
Price: $368/5mg
3'-Hydroxymirificin

Catalog No: CFN95102
CAS No: 168035-02-7
Price: $338/5mg
Peiioside B

Catalog No: CFN95336
CAS No: 1610618-91-1
Price: $318/5mg
Dehydrojuncusol

Catalog No: CFN95143
CAS No: 117824-04-1
Price: $318/5mg
Decursitin D

Catalog No: CFN95002
CAS No: 245446-61-1
Price: $388/5mg
Solafuranone

Catalog No: CFN95312
CAS No: 367965-50-2
Price: $318/5mg
Methyl ganoderenate D

Catalog No: CFN95572
CAS No: 748136-03-0
Price: $413/5mg
(Z)-Ferulic acid 4-O-beta-D-glucos...

Catalog No: CFN95546
CAS No: 94942-20-8
Price: $318/10mg
Recently, ChemFaces products have been cited in many studies from excellent and top scientific journals

Cell. 2018 Jan 11;172(1-2):249-261.e12.
doi: 10.1016/j.cell.2017.12.019.
IF=36.216(2019)

PMID: 29328914

Cell Metab. 2020 Mar 3;31(3):534-548.e5.
doi: 10.1016/j.cmet.2020.01.002.
IF=22.415(2019)

PMID: 32004475

Mol Cell. 2017 Nov 16;68(4):673-685.e6.
doi: 10.1016/j.molcel.2017.10.022.
IF=14.548(2019)

PMID: 29149595

ACS Nano. 2018 Apr 24;12(4): 3385-3396.
doi: 10.1021/acsnano.7b08969.
IF=13.903(2019)

PMID: 29553709

Nature Plants. 2016 Dec 22;3: 16206.
doi: 10.1038/nplants.2016.205.
IF=13.297(2019)

PMID: 28005066

Sci Adv. 2018 Oct 24;4(10): eaat6994.
doi: 10.1126/sciadv.aat6994.
IF=12.804(2019)

PMID: 30417089
Calculate Dilution Ratios(Only for Reference)
1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.1513 mL 10.7566 mL 21.5132 mL 43.0265 mL 53.7831 mL
5 mM 0.4303 mL 2.1513 mL 4.3026 mL 8.6053 mL 10.7566 mL
10 mM 0.2151 mL 1.0757 mL 2.1513 mL 4.3026 mL 5.3783 mL
50 mM 0.043 mL 0.2151 mL 0.4303 mL 0.8605 mL 1.0757 mL
100 mM 0.0215 mL 0.1076 mL 0.2151 mL 0.4303 mL 0.5378 mL
* Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
Protocol
Kinase Assay:
Int J Cancer. 2015 Mar 15;136(6):1434-44.
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.[Pubmed: 25080865]
The multikinase inhibitor Sorafenib is under clinical investigation for the treatment of many solid tumors, but in most cases, the molecular target responsible for the clinical effect is unknown. Furthermore, enhancing the effectiveness of Sorafenib using combination strategies is a major clinical challenge.
METHODS AND RESULTS:
Here, we identify Sorafenib as an activator of AMP-activated protein kinase (AMPK), in a manner that involves either upstream LKB1 or CAMKK2. We further show in a phase II clinical trial in KRAS mutant advanced non-small cell lung cancer (NSCLC) with single agent Sorafenib an improved disease control rate in patients using the antidiabetic drug metformin. Consistent with this, Sorafenib and metformin act synergistically in inhibiting cellular proliferation in NSCLC in vitro and in vivo. A synergistic effect of both drugs is also seen on phosphorylation of the AMPKα activation site. Our results provide a rationale for the synergistic antiproliferative effects, given that AMPK inhibits downstream mTOR signaling.
CONCLUSIONS:
These data suggest that the combination of Sorafenib with AMPK activators could have beneficial effects on tumor regression by AMPK pathway activation. The combination of metformin or other AMPK activators and Sorafenib could be tested in prospective clinical trials.
Animal Research:
Exp Cell Res. 2015 Feb 1;331(1):97-104.
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.[Pubmed: 25447203]
Treatment outcome of children with pediatric hepatocellular carcinoma (pHCC) is poor. Therefore, we evaluated the tyrosine kinase inhibitor Sorafenib in a model of pHCC.
METHODS AND RESULTS:
Cell viability after treatment with Sorafenib was evaluated in HC-AFW1 cells (pHCC) using MTT assay and compared to an adult HCC (aHCC) and two hepatoblastoma (HB) cell lines. ERK, pERK, E-cadherin, and vimentin expression were investigated using Western Blot. Sorafenib (60 mg/kg) was administered orally to NOD.Cg-Prkdcscid-IL2rgtmWjl/Sz mice bearing subcutaneous HC-AFW1-derived tumors. Tumor progression, viability, and vascularization were monitored by tumor volume, AFP levels, and CD31 immunostaining, respectively. Sensitization to Sorafenib was evaluated using the β-catenin inhibitor ICG001. Sorafenib reduced cell viability in HC-AFW1 (IC50: 8 µM), comparable to HB cells, however less pronounced in aHCC cells (IC50: 23 µM). Sorafenib inhibited ERK signaling in both, HC-AFW1 cells and -xenografts. In vivo, Sorafenib treatment only led to a moderate tumor growth inhibition, although significant reduction of vascularization and tumor growth kinetics was observed. Long-term treatment with Sorafenib decreased E-cadherin, but showed no induction of vimentin expression. Combining Sorafenib with a β-catenin inhibitor led to an additional reduction of cell viability.
CONCLUSIONS:
Sorafenib together with inhibitors of the β-catenin pathway might be an effective tool in the treatment of pediatric HCC.
Rhapontigenin

Catalog No: CFN92607
CAS No: 500-65-2
Price: $118/20mg
L-Valine

Catalog No: CFN94831
CAS No: 72-18-4
Price: $30/20mg
Procyanidin A1

Catalog No: CFN96495
CAS No: 103883-03-0
Price: $288/20mg
Calycosin

Catalog No: CFN99140
CAS No: 20575-57-9
Price: $80/20mg
Diallyl disulfide

Catalog No: CFN93237
CAS No: 2179-57-9
Price: $50/20mg
Platycoside E

Catalog No: CFN90786
CAS No: 237068-41-6
Price: $ / mg
Mangiferin

Catalog No: CFN98719
CAS No: 4773-96-0
Price: $40/20mg
Ginkgolide B

Catalog No: CFN99640
CAS No: 15291-77-7
Price: $40/20mg
Chebulinic acid

Catalog No: CFN92296
CAS No: 18942-26-2
Price: $138/20mg
Oxypeucedanin

Catalog No: CFN90350
CAS No: 737-52-0
Price: $80/20mg
Tags: buy Sorafenib | Sorafenib supplier | purchase Sorafenib | Sorafenib cost | Sorafenib manufacturer | order Sorafenib | Sorafenib distributor